Article

A phase I trial of Ad.hIFN-beta gene therapy for glioma

Department of Neurosurgery, Dardinger Neuro-oncology Center, James Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, Ohio 43210-1240, USA.
Molecular Therapy (Impact Factor: 6.43). 04/2008; 16(3):618-26. DOI: 10.1038/sj.mt.6300396
Source: PubMed

ABSTRACT Interferon-beta (IFN-beta) is a pleiotropic cytokine with antitumoral activity. In an effort to improve the therapeutic index of IFN-beta by providing local, sustained delivery of IFN-beta to gliomas, the safety and biological activity of a human IFN-beta (hIFN-beta)-expressing adenovirus vector (Ad.hIFN-beta) was evaluated in patients with malignant glioma by stereotactic injection, followed 4-8 days later by surgical removal of tumor with additional injections of Ad.hIFN-beta into the tumor bed. Eleven patients received Ad.hIFN-beta in cohorts of 2 x 10(10), 6 x 10(10), or 2 x 10(11) vector particles (vp). The most common adverse events were considered by the investigator as being unrelated to treatment. One patient, who was enrolled in the cohort with the highest dose levels, experienced dose-limiting, treatment-related Grade 4 confusion following the post-operative injection. Ad.hIFN-beta DNA was detected within the tumor, blood, and nasal swabs in a dose-dependent fashion and hIFN-beta protein was detectable within the tumor. At the highest doses tested, a reproducible increase in tumor cell apoptosis in post-treatment versus pre-treatment biopsies with associated tumor necrosis was observed. Direct Ad.hIFN-beta injection into the tumor and the surrounding normal brain areas after surgical removal was feasible and associated with apoptosis induction.

Download full-text

Full-text

Available from: Kevin Owen Lillehei, Aug 22, 2014
0 Followers
 · 
116 Views
  • Source
    • "For example, immunotherapeutic treatments utilizing DC vaccines pulsed with whole tumor homogenate [112] or tumor-specific peptides, such as for EGFRvIII, [113-115] owe their translational origins to successful studies using the GL261 model [84,116-119]. Other clinical trials for targets such as TGF-β [120,121] and gene therapeutic approaches [122] also have origins in preclinical studies using the SMA-560 [123] and GL261 models, [124,125] respectively. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (JAMA 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes are modest, in no small part due to tumor-induced immunosuppressive mechanisms that promote immune escape and immuno-resistance. Immunotherapeutic strategies aimed at bolstering the immune response while neutralizing immunosuppression will play a critical role in improving treatment outcomes for glioblastoma patients. In vivo murine models of glioma provide an invaluable resource to achieving that end, and their use is an essential part of the preclinical workup for novel therapeutics that need to be tested in animal models prior to testing experimental therapies in patients. In this article, we review five contemporary immunocompetent mouse models, GL261 (C57BL/6), GL26 (C57BL/6) CT-2A (C57BL/6), SMA-560 (VM/Dk), and 4C8 (B6D2F1), each of which offer a suitable platform for testing novel immunotherapeutic approaches.
    Journal of Translational Medicine 04/2014; 12(1):107. DOI:10.1186/1479-5876-12-107 · 3.99 Impact Factor
  • Source
    • "Author's personal copy antigens (TAAs), or other immunomodulatory elements, oncolytic viruses (OVs) have been shown in various preclinical models to induce antigenspecific effector and memory responses, resulting both in full therapeutic cures and even induction of life-long tumor immunity (Kaur, Cripe, & Chiocca, 2009; Liu et al., 2011; Prestwich, Harrington, Pandha, et al., 2008; Prestwich, Harrington, Vile, & Melcher, 2008; Tuve et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adenovirus is one of the most commonly used vectors for gene therapy and two products have already been approved for treatment of cancer in China (Gendicine(R) and Oncorine(R)). An intriguing aspect of oncolytic adenoviruses is that by their very nature they potently stimulate multiple arms of the immune system. Thus, combined tumor killing via oncolysis and inherent immunostimulatory properties in fact make these viruses in situ tumor vaccines. When further engineered to express cytokines, chemokines, tumor-associated antigens, or other immunomodulatory elements, they have been shown in various preclinical models to induce antigen-specific effector and memory responses, resulting both in full therapeutic cures and even induction of life-long tumor immunity. Here, we review the state of the art of oncolytic adenovirus, in the context of their capability to stimulate innate and adaptive arms of the immune system and finally how we can modify these viruses to direct the immune response toward cancer.
    Advances in Cancer Research 01/2012; 115:265-318. DOI:10.1016/B978-0-12-398342-8.00008-2 · 4.26 Impact Factor
  • Source
    • "The need for improved local tumour control is reflected by the number of clinical trials that have been performed involving the instillation of chemotherapeutics locally into the brain. These have included the direct infusion or implantation of conventional chemotherapeutics such as carmustine [5], paclitaxel [6] and topotecan [7], or novel cytotoxic agents, including oncolytic herpes simplex and adenoviral vectors [8] [9] [10] [11] [12], viral and non-viral mediated gene therapy [13] [14] [15] [16], and immunotoxins such as IL13-PE38QQR [17], into the tumour mass, resection cavity or peritumoural tissue. To date, the only technique of localised drug delivery that has become clinically useful is the implantation of carmustine wafers (Gliadel) into the tumour resection cavity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glioblastoma multiforme (GBM) is the commonest primary malignant brain tumour in adults. Standard treatment comprises surgery, radiotherapy and chemotherapy; however this condition remains incurable as these tumours are highly invasive and involve critical areas of the brain making it impossible to remove them surgically or cure them with radiotherapy. In the majority of cases the tumour recurs within 2 to 3 cm of the original site of tumour resection. Furthermore, the blood-brain barrier profoundly limits the access of many systemically administered chemotherapeutics to the tumour. Convection-enhanced delivery (CED) is a promising technique of direct intracranial drug delivery involving the implantation of microcatheters into the brain. Carboplatin represents an ideal chemotherapy to administer using this technique as glioblastoma cells are highly sensitive to carboplatin in vitro at concentrations that are not toxic to normal brain in vivo. This protocol describes a single-centre phase I dose-escalation study of carboplatin administered by CED to patients with recurrent or progressive GBM despite full standard treatment. This trial will incorporate 6 cohorts of 3 patients each. Cohorts will be treated in a sequential manner with increasing doses of carboplatin, subject to dose-limiting toxicity not being observed. This protocol should facilitate the identification of the maximum-tolerated infused concentration of carboplatin by CED into the supratentorial brain. This should facilitate the safe application of this technique in a phase II trial, treating patients with GBM, as well as for the treatment of other forms of malignant brain tumours, including metastases.
    Contemporary clinical trials 11/2011; 33(2):320-31. DOI:10.1016/j.cct.2011.10.010 · 1.99 Impact Factor
Show more